therapy and stem cell support appears possible. Peters et al 2,3 reported a 78% overall survival (OS) in this high-risk breast cancer subgroup after high-dose chemotherapy folTwenty-one high-risk patients with primary stage II/III breast cancer were treated with high-dose chemolowed by stem cell support (median follow-up 4.5 years).
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Preparation and immunostaining of bone marrow specimens and stem cell collections
Bone marrow samples were aspirated from both posterior Amgen, Munich, Germany) 5 g/kg was administered by iliac crests at the time of primary surgery. A mean volume subcutaneous injection, starting day 1 after chemotherapy of 5 ml bone marrow aspirate from both upper posterior until the time of stem cell collection. Peripheral blood stem iliac crests was taken into syringes containing 100 units cells (PBSC) were collected in an outpatient setting by leuheparin/ml marrow, yielding between 5 × 10 6 and 3 × 10 7 kapheresis on day 10 and/or 11 after each induction chemo-(mean 10 7 ) mononuclear cells. After dilution with 10 ml therapy cycle. Leukaphereses were performed with a blood phosphate buffered saline (PBS), marrow fat was separated cell separator (AS 104, Fresenius, Oberursel, Germany).
by centrifugation (180 g, 10 min). After density centrifugAcid citrate dextrose (ACD) anticoagulant (in a concenation through Ficoll-Hypaque (Seromed, Berlin, Germany; tration ACD:0.9% sodium chloride = 1:15, Fresenius, density 1.077, 900 g, 30 min) mononuclear cells were colOberursel, Germany; 440 ml per leukapheresis) was used.
lected from the interphase. Washed twice in PBS and cen-6.6 liters blood were processed per leukapheresis. Stem trifuged (200 g, 10 min), the cells were then suspended with cells were collected with a total volume of 220 ml on each 1-5 ml PBS yielding a concentration of 2 × 10 6 cells/ml. In day of leukapheresis, counted, mixed with 50 ml autologa cytocentrifuge (Hettich, Tuttlingen, Germany) an average ous plasma, 150 ml hemofusin 10% (Pharmacia, Erlangen, number of 1 × 10 6 cells was centrifuged onto glass slides. Germany), 50 ml DMSO (Merck, Darmstadt, Germany)
After air drying for 12-24 h and acetone fixation (10 min, room temperature), two slides comprising 2 × 10 6 nucleated cells were routinely examined for each patient. One additional slide served as IgG isotype control. Immunostaining with the moAb (CK2 (IgG 1 ) (Boehringer Mannheim, Tutzing, Germany) directed against the cytokeratin polypeptide 18 (CK18), 14,15 and the broad-spectrum moAb A45-B/B3 (IgG 1 ) (kindly provided by Micromet, Munich, Germany), [16] [17] [18] directed against a common epitope on a variety of cytokeratin components, including CK8, 18 and 19 was used for tumor cell detection in bone marrow and in PBSC cytospin preparations. 10, 19 The antibody reaction was developed with the alkaline phosphatase-antialkaline phosphatase (APAAP) technique.
Stem cell collections after 1st and/or 2nd cycle of induction chemotherapy were analyzed as described for BM specimens. After density centrifugation through Ficoll- slides followed by air drying and acetone fixation. For each PBSCT, two of these slides comprising 2 × 10 6 cells were ber of CK positive cells in each transplant is shown in examined after immunostaining with the moAbs CK2 and Table 2 . Altogether 14 of 35 transplants analyzed (40%) A45-B/B3. The tested sensitivity of our method was the showed CK positive cells as a sign of tumor cell contamidetection of one tumor cell among 2 × 10 6 normal bone nation. In the 14 patients with stem cell separates collected marrow cells or 2 × 10 6 cells of the PBSCT aliquots. The after both the 1st and 2nd induction chemotherapy cycle, cytoplasm of the tumor cells stained bright orange-red. tumor cells were found on an average of 2.25 CK positive Positive smears were defined as those containing one or cells per 2 × 10 6 cells analyzed after the 1st and on an avermore tumor cells. In bone marrow samples one to nine cells age of 1.5 CK positive cells per 2 × 10 6 transplant cells anawere detected for most positive smears and in the PBSCT lyzed after the 2nd cycle. Extent of tumor cell positivity one to five cells per slide. All slides included in our study of the transplants obtained after the 1st cycle of induction were read by two independent investigators, with an interchemotherapy yields 64.3% (9/14 patients), but after the observer agreement of 99%.
2nd cycle only 14.3% (2/14 patients). The cumulative number of CK positive cells of the patients with transplants separated after the 1st and 2nd induction cycle is presented Results in Figure 1 . The lower number of CK positive cells in the second stem cell separate is apparent. Stratifying the posiTo date, 21 patients with high-risk breast cancer stage II/III tive transplants according to tumor stage, revealed no correhave been treated with high-dose chemotherapy and stem lation. We carried out follow-up analysis of all patients. cell support. Therapy can be administered safely without
The median follow-up is 13.57 months (4-27). To date 17 major side-effects. After each induction chemotherapy, perpatients are in complete remission, four patients experiipheral blood stem cells mobilized by G-CSF were harenced a relapse, two patients died due to tumor relapse. transplants. However, these results are not statistically stem cell harvest. One transplant separated after the first significant due to the low patient number. and one after the second cycle of induction chemotherapy were not assessable for cytokeratin positive cells. The num- Table 2 Cytokeratin positive tumor cells a in bone marrow (BM) and peripheral stem cell transplants (PBSCT) reponsible for this phenomenon. Crossreactivity of CK moAbs with hematopoietic cells was excluded in previous double-marker analyses, demonstrating exclusive positivity of CK components and a simultaneous lack of CD45 and vimentin. 10, 11, 19 On the other hand, CK positive cells showed tumor-associated characteristics, such as downregulation of MHC class I antigens and overexpression of the erbB2 oncogene. 10, 33 Furthermore, combination of ICC and fluorescence in situ hybridization (FISH) demonstrated amplification of the erb-B2 gene in disseminated tumor cells in bone marrow samples of breast cancer patients. 34 Theoretically, polymerase chain reaction analysis (PCR) may overshadow the well-demonstrated specificity and sensitivity of immunocytochemical assays for detection of approximately 1 log greater sensitivity compared to the ICC method, but increased sensitivity may decrease specificity. 32 The specificity of RT-PCR may not be absolute but Discussion may rather reflect quantitative differences in the level of expression of malignant cells and the surrounding autochAutologous peripheral blood stem cell transplantation permits an alternative to bone marrow transplantation for thonous cells. 37 Thus, amplification of pseudogenes 19 or illegitimate transcription of CK19 by mononuclear cells patients treated with high-dose chemotherapy in solid tumors and hematological malignancies. Main advantages decrease the specificity of RT-PCR. 38 Similarly, genes encoding for other tumor-associated molecules may not be of this method are the ready availability of peripheral blood stem cells and their more rapid hematopoietic engraftment.
expressed uniquely in tumor cells but may also exert some mRNA expression in certain normal tissues. [39] [40] [41] [42] [43] The rate After chemotherapy and use of growth factors, peripheral blood stem cells can be processed and harvested in large of false-positive findings can be lowered by decreasing the number of PCR cycles and by using fewer cells, but this amounts. Chemotherapy followed by growth factor administration may mobilize tumor cells into peripheral blood. 5 modification automatically limits the sensitivity of the method. 32 Zippelius et al 40, 41 revealed that the RT-PCR Notably, residual tumor cells can be detected in bone marrow in about 30% of patients with curatively resected solid assay in BM specimens of patients with prostate or colorectal cancer was less sensitive than the standard immunocytotumors. 20 In breast cancer patients, minimal residual disease in bone marrow is an independent prognostic factor for dischemical cytokeratin assay. 10 At the present time, ICC is the best method for detecting isolated disseminated tumor ease-free and overall survival.
21-25 Thus, a possible cause of tumor relapse in patients treated with high-dose chemocells in hematopoietic tissues, and PCR methods are best for demonstrating negativity for micrometastasis. 32 therapy and stem cell rescue could be the reinfusion of these contaminating tumor cells. 5, 21, [26] [27] [28] The reinfusion of We attempted to detect tumor cell contamination immunocytochemically in peripheral blood stem cell harvests of malignant cells by autologous bone marrow transplantation has been shown to be a prognostic factor for relapse in B breast cancer patients by using moAbs directed against CK components. Peripheral blood stem cells were harvested cell lymphoma by Gribben et al 29 and in acute myeloid leukemia by Brenner et al. 30 Minimal residual disease in after the 1st and the 2nd induction cycles with VIP-E chemotherapy followed each time by stimulation with Gbreast cancer patients can be detected by immunocytochemistry. 31 The sensitivity of immunocytochemical (ICC) CSF. The higher tumor cell contamination of the stem cell harvests obtained after the 1st cycle of induction chemomethods for tumor cell detection is limited by the number of cells examined. The 95% confidence limit of sensitivity therapy compared to the 2nd indicates that chemotherapy is capable of reducing minimal residual tumor cell load (in is about one tumor cell in 10 6 nucleated cells for 3 × 10 6 cells examined. 32 In immunocytochemical analyses, the vivo purging). The number of CK positive cells was higher in bone marrow compared to PBSC harvests. These data specificity of moAbs against cytokeratin (CK), the cytoskeleton of epithelial cells, has been shown to be superior confirm the results of other authors. 7, 44, 45 The prognostic meaning of epithelial tumor cells in peripheral blood stem when compared with that of moAbs directed against cell surface antigens such as the epithelial membrane antigen cell transplants (PBSCT) is, in contrast to bone marrow, as yet unknown. 21 Ross et al 44, 45 revealed that tumor cells in (EMA), the human epithelial antigen (HEA) 125 or the tumor associated glycoprotein (TAG) 72, which may both marrow and PBSC collections appear to be capable of clonogenic growth in vitro, thus possibly contributing to crossreact with hematopoietic cells. 10, 19 
